PharmacoMRI of Parkinson Disease

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Based on studies showing better responsiveness of motor versus cognitive symptoms to Parkinson's Disease medication, also known as dopaminergic treatments, the investigators hypothesize that comparison of resting state networks in the on versus off medication state in Parkinson's Disease patients will show greater effects on brain networks associated with motor control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

NCT00404170

Parkinson Disease

COMPLETED PHASE2

FDOPA PET and Nutritional Support in Parkinson's Disease

NCT04459052

Parkinson Disease Idiopathic Parkinson Disease

ACTIVE_NOT_RECRUITING PHASE2

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease

NCT00129181

Parkinson Disease Parkinsonian Syndrome

COMPLETED NA

Imaging Depression in Parkinson's Disease

NCT06402955

Parkinson's Disease Major Depressive Disorder

RECRUITING PHASE2

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

NCT00117819

Parkinsonian Syndrome

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subject participation includes two 25-30 minute MRI scans. The subject will arrive in the "off" state (PD medications withheld for approximately 12 hours prior to the scan). Following the initial scan, the subject will receive 125% of his or her usual daily morning dose of PD medications which is calculated as levodopa dose equivalents (LDE) and is given as carbidopa-levodopa. The subject will then wait for an hour allowing for the medication to begin working. During this time the subject will complete cognitive assessments, questionnaires regarding the history and current state of PD, and motor assessments. The subject will then undergo a second MRI scan of approximately 25-30 minutes. The subject after completing the second MRI scan is free to leave. The entire study is approximately 2 and 1/2 hours long.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

On / Off medication

Subjects undergo MRI scanning in the medication off state and 1 hour after receiving medications.

Group Type EXPERIMENTAL

Carbidopa-Levodopa

Intervention Type DRUG

Equivalent amount of carbidopa-levodopa will be provide to you

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carbidopa-Levodopa

Equivalent amount of carbidopa-levodopa will be provide to you

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Idiopathic Parkinson's Disease (PD)
* Older than 30 years of age at the time of diagnosis
* Hoehn and Yahr stage greater than or equal to 2.5
* PD duration greater than 3 years
* Stable regimen of PD medications for at least 2 weeks prior to imaging
* PD medications include carbidopa-levodopa

Exclusion Criteria

* Patients with a diagnosis of other neurodegenerative conditions
* Patients unwilling or unable to give informed consent
* Contraindications (cardiac pacemaker, etc.) or inability (e.g., claustrophobia) to undergo MRI scan

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No